Steven M. Keller

6.7k citations

102 papers · 3.7k indexed · 2 hit papers · h-index 31

Pulmonary and Respiratory Medicine top 0.5%
Oncology top 2%
Surgery top 5%
Molecular Biology
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: David H. Johnson Sudeshna Adak Henry Wagner Robert B. Livingston Corey J. Langer Walter J. Curran Michael C. Perry Arnold Herskovic
Topics: Lung Cancer Diagnosis and Treatment (46 papers)Lung Cancer Treatments and Mutations (44 papers)Cancer Immunotherapy and Biomarkers (12 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Otorhinolaryngology
Journals: New England Journal of Medicine Journal of the American Chemical Society Journal of Clinical Oncology
Partner nations: United States South Korea Spain

In The Last Decade

Steven M. Keller

99 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Ayman Samkari, Steven M. Keller et al. profile →

Peers

Countries citing papers authored by Steven M. Keller

Since Specialization

Citations

This map shows the geographic impact of Steven M. Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Keller more than expected).

Fields of papers citing papers by Steven M. Keller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Keller. The network helps show where Steven M. Keller may publish in the future.

Co-authorship network of co-authors of Steven M. Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Keller. A scholar is included among the top collaborators of Steven M. Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Keller. Steven M. Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Marina Chiara Garassino,Heather A. Wakelee,Jonathan Spicer,Moïshe Liberman,Terufumi Kato,Masahiro Tsuboi,Se‐Hoon Lee,Ke‐Neng Chen,(unknown),Margarita Majem,E. Eigendorff,Gastón Lucas Martinengo,Olivier Bylicki,Delvys Rodríguez‐Abreu,Jamie E. Chaft,Jing Yang,Ashwini Arunachalam,Josephine M. Norquist,Steven M. Keller,Shugeng Gao	2
2	KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. 2023 ·Journal of Clinical Oncology ·Heather A. Wakelee,Moïshe Liberman,Terufumi Kato,Masahiro Tsuboi,Se‐Hoon Lee,Jie He,Shugeng Gao,Ke‐Neng Chen,(unknown),Margarita Majem,E. Eigendorff,Gastón Lucas Martinengo,Olivier Bylicki,Delvys Rodríguez‐Abreu,Jamie E. Chaft,Silvia Novello,Jing Yang,Steven M. Keller,Ayman Samkari,Jonathan Spicer	11
3	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial 2021 ·Journal of Thoracic Oncology ·Conor Steuer,Opeyemi A. Jegede,Suzanne E. Dahlberg,Heather A. Wakelee,Steven M. Keller,William Tester,David R. Gandara,Stephen L. Graziano,Alex A. Adjei,Charles Butts,Suresh S. Ramalingam,Joan H. Schiller	8
4	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Hossein Borghaei,Corey J. Langer,Shirish M. Gadgeel,Vassiliki A. Papadimitrakopoulou,Amita Patnaik,Steven Powell,Ryan D. Gentzler,Renato Martins,James Stevenson,Shadia I. Jalal,Amit Panwalkar,James Chih‐Hsin Yang,Matthew A. Gubens,Lecia V. Sequist,Mark M. Awad,Joseph Fiore,Sanatan Saraf,Steven M. Keller,Leena Gandhi	169
5	Genome Wide Methylome Alterations in Lung Cancer 2015 ·PLoS ONE ·Nandita Mullapudi,Bin Ye,Masako Suzuki,Melissa Fazzari,Weiguo Han,Miao Shi,(unknown),Juan Lin,Tao Wang,Steven M. Keller,Changcheng Zhu,Joseph Locker,Simon D. Spivack	27
6	Association of Patient–Provider Communication Domains with Lung Cancer Treatment 2014 ·Journal of Thoracic Oncology ·Jenny J. Lin,(unknown),Melanie M. Wall,Andrew Berman,John Salazar‐Schicchi,Charles A. Powell,Steven M. Keller,Ethan A. Halm,Howard Leventhal,Juan P. Wisnivesky	18
7	Cultural Factors Associated with Racial Disparities in Lung Cancer Care 2014 ·Annals of the American Thoracic Society ·Jenny J. Lin,Grace Mhango,Melanie M. Wall,Linda Lurslurchachai,Keosha T. Bond,Judith E. Nelson,Andrew Berman,John Salazar‐Schicchi,Charles A. Powell,Steven M. Keller,Ethan A. Halm,Howard Leventhal,Juan P. Wisnivesky	74
8	Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer 2010 ·Clinical Cancer Research ·Thomas M. Harris,Qiulu Pan,Juan Sironi,(unknown),Jianmin Tian,(unknown),Román Pérez-Soler,Steven M. Keller,Joseph Locker	38
9	Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non–Small Cell Lung Cancer 2008 ·Thoracic surgery clinics/Thorac. surg. clin. ·(unknown),Steven M. Keller	3
10	Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression 2007 ·Cancer Research ·(unknown),Chia‐Ping Huang Yang,(unknown),Lluís López-Barcons,Steven M. Keller,Román Pérez-Soler,Susan Band Horwitz,Hayley M. McDaid	66
11	Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590 2007 ·Lung Cancer ·Daniel B. Costa,Sigui Li,Olivier Kocher,Richard H. Feins,Steven M. Keller,Joan H. Schiller,David H. Johnson,Daniel G. Tenen,Balázs Halmos	17
12	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer 2006 ·Journal of Thoracic Oncology ·Sarita Dubey,Patricia Stephenson,Donna E. Levy,Judith Miller,Steven M. Keller,Joan H. Schiller,David H. Johnson,Jill Kolesar	32
13	Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants 2005 ·Cancer Research ·Hayley M. McDaid,Lluís López-Barcons,Aaron Grossman,Marie Lia,Steven M. Keller,Román Pérez-Soler,Susan Band Horwitz	72
14	Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 2005 ·Lung Cancer ·Heather A. Wakelee,Patricia Stephenson,Steven M. Keller,Henry Wagner,Arnold Herskovic,Ritsuko Komaki,Randolph S. Marks,Michael C. Perry,Robert B. Livingston,David H. Johnson	42
15	Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease 2004 ·Journal of Thoracic and Cardiovascular Surgery ·Steven M. Keller,Márk Vangel,Henry Wagner,Joan H. Schiller,Arnold Herskovic,Ritsuko Komaki,Randolph S. Marks,Michael C. Perry,Robert B. Livingston,David H. Johnson	72
16	Adjuvant therapy of resected non–small-cell lung cancer 2000 ·Current Opinion in Oncology ·Steven M. Keller	5
17	Epidural Narcotic Analgesia After Thoracotomy 1993 ·Southern Medical Journal ·(unknown),(unknown),Steven M. Keller	2
18	Cytogenetic abnormalities in non‐small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures 1993 ·Genes Chromosomes and Cancer ·Jill M. Siegfried,Jay D. Hunt,Jianyuan Zhou,Steven M. Keller,Joseph R. Testa	6
19	Intrathoracic organ injury associated with photodynamic therapy 1992 ·Journal of Thoracic and Cardiovascular Surgery ·(unknown),Michael J. Kowalyshyn,Steven M. Keller	21
20	DNA content in correlation with postsurgical stage in non-small cell lung cancer 1992 ·The Annals of Thoracic Surgery ·Ned Z. Carp,(unknown),(unknown),Perry Watts,(unknown),Steven M. Keller	25

About Steven M. Keller

Steven M. Keller is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology, having authored 102 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (46 papers), Lung Cancer Treatments and Mutations (44 papers) and Cancer Immunotherapy and Biomarkers (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.5k citations), Oncology (1.5k citations) and Otorhinolaryngology (148 citations). Steven M. Keller has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include David H. Johnson, Sudeshna Adak, Henry Wagner, Robert B. Livingston, Corey J. Langer, Walter J. Curran, Michael C. Perry, Arnold Herskovic, Wyatt C. Fowler and Ritsuko Komaki. Their work appears in journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact